E.g., 11/15/2019
E.g., 11/15/2019
Title Category Credit Event date Price
Life Long Learning Knowledge Assessment Course: Urothelial Bladder Cancer Webcast (2018)
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 Non-Physician Participation
$99.00 This activity was taken from the 2017 Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam.
Life Long Learning Prep Course: A Focused Review Webcast - Module 1: Oncology, Urinary Diversion and Adrenal (2019) $1,045.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems Webcast 072IC (2019)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will review the most recent AUA practice guidelines for non-muscle-invasive bladder cancer and detail strategies to manage common clinical predicaments involved in the management of these tumors. Specifically we will review: the AUA guidelines; risk stratification and use of cystectomy; selection of the optimal intravesical agent at the right schedule; and treatment of toxicity from intravesical therapy. Practical solutions will be presented that can be readily integrated into the office setting.
Multi-parametric Ultrasound in the Diagnosis of Prostate Cancer Webcast (2017)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! Transrectal ultrasound is critical to biopsy guidance for the diagnosis of prostate cancer. However, ultrasound has the ability to improve diagnostic accuracy and may perform as well as multi-parametric MRI in identifying suspicious lesions. This course will familiarize participants with gray-scale ultrasound, color and power Doppler ultrasound, elastography and contrast-enhanced ultrasound as modalities which alone or in combination may improve the diagnosis of prostate cancer. 
New Muscle Invasive Bladder Cancer Guideline Webcast (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Novel Agents & Concepts in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer Webcast 048IC (2019)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.ACKNOWLEDGEMENTSSupport provided by independent educational grants from:
Practical Management of Metastatic Prostate Cancer: Guidelines and Beyond Webcast (2017) $0.00 Urologists continue to indicate one of the greatest educational needs in treating CRPC patients is the sequencing of agents. With the numerous new treatments now available to urologists to manage the CRPC patient, sequencing and managing the side effects of each treatment have become increasingly important. In addition, studies are demonstrating that earlier treatment with these systemic agents has improved efficacy.
Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion (2017)
    • 6.50 AMA PRA Category 1 Credit™
    • 6.50 Non-Physician Participation
$1,345.00 Specifically designed for anyone unable to get away from the office to attend the Live Course—the Webcast option delivers the same great content. Purchase of  the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Robotic Urologic Surgery: A Technical Masterclass Webcast (2018) $689.00 Robotic Urologic Surgery: A Technical Masterclass provides a structured approach to advanced robotic surgery for conditions of the prostate, kidney, and bladder with an emphasis on radical prostatectomy and partial nephrectomy. This course will also focus on emerging technologies including genomic testing and advanced imaging. Experienced world-class faculty with more than a decade of experience with complex robotic surgery will provide you with instruction to refine your technique and achieve superior results.
Self-Assessment Study Program SASP (2018) $280.00 The SASP is the AUA’s most popular study tool for exam preparation! To meet your learning preference, the SASP is available in three convenient formats—booklet, online, and the innovative Q-Stream format which sends questions directly to your smartphone, computer or tablet. Pricing will be displayed upon format selection. Offering up to 20 AMA PRA Category 1 Credits™.
Self-Assessment Study Program SASP (2019) $295.00 The SASP is the AUA’s most popular study tool for exam preparation! 
Sequencing of Agents and Combination Therapy in Prostate Cancer Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
The Journal of Urology® Volumes 197/198 Home Study Course (2017)
    • 24.00 AMA PRA Category 1 Credit™
    • 24.00 Non-Physician Participation
$60.00 Most Comprehensive and Affordable Self-study CME Product!Make the most of your Journal of Urology® SubscriptionDeveloped by a team of educators, academicians, and clinicians, this valuable home study activity will enhance your knowledge of urology and improve performance as well as patient care at your convenience. For just $2.50 per credit, the Home Study program is designed to provide urologists and residents affordable access to the most recent developments and techniques in urology while reading The Journal®.
The Role of Immune Checkpoint Inhibitors in Bladder Cancer Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Therapeutic Advances in Immuno-Oncology (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The American Urological Association (AUA) and Società Italiana di Urologia (SIU) have collaborated to develop an independent educational activity to review the latest updates in immuno-oncology.  This one hour course is designed to improve clinicians’ understanding of current immunotherapeutic agents for the treatment of GU cancers, improve patient outcomes, and the management of adverse events. The course covers the following topics: 

Pages